Dr. Jane Osbourn OBE - CHAIR

Dr. Jane Osbourn OBE

CHAIR

Jane has over 30 years of experience in biologics discovery and development. Most recently, she was Vice President for R&D and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology.

Jane is a scientific leader in the field of antibody engineering and has made a significant contribution to the discovery and development of eight marketed drugs and over 40 clinical candidates. Jane is passionate about science education and the development of the UK biotech sector and served as Chair of the Board of Directors of the BioIndustry Association for four years before taking on a Corporate Board Member role earlier this year. She is currently a Director of Babraham Bioscience Technologies, and also a Director of Cambridge Enterprise. She was awarded Scrip’s Lifetime Achievement Award and an OBE in 2019 for services to drug discovery, development and biotechnology.

Dr. Darrin M. Disley OBE - CEO

Dr. Darrin M. Disley OBE

CEO

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown or invested in over 40 start-up life science, technology and social enterprises, raising $525 million USD in business financing and closing $650 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was awarded a lifetime Queen’s Award for Enterprise Promotion in 2016 for his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.

Dr. Karin Schmitt - CBO

Dr. Karin Schmitt

CBO

Karin is a globally experienced science and business executive with more than 25 years of diverse experience in biotech drug discovery, platform development and medical device companies. With a recent emphasis on cell and gene therapy, her career spans the Boston area, Silicon Valley and the Cambridge cluster. Karin has been an early employee in several successful start-ups, including Millennium Pharmaceuticals, Exelixis and Horizon Discovery making significant contributions to the rapid growth of these companies to IPO and beyond. Karin obtained her PhD in molecular biology at the University of Southern California in Los Angeles, followed by three years of post-doctoral research in genetics at the University of Cambridge.

Prof. Julian Gough - CTO (Co-founder)

Prof. Julian Gough

CTO (Co-founder)

Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.

Dr. Lorenz Mayr

DR. LORENZ MAYR

Non-Executive Director

Dr. Mayr has over 30 years’ experience in biopharma research, development and commercialization. Most recently, he was Chief Technology Officer at GE Healthcare Life Sciences, where he was responsible for research investments, talent development and company growth strategy across all business areas. His former positions include Vice President & Global Head at AstraZeneca, where he oversaw the generation of biological reagents and assay development activities across all therapeutic areas, and Executive Director at Novartis.

Lorenz is a biochemistry lecturer at the Martin Luther University Halle-Wittenberg and has published over 60 peer-reviewed papers.

Alastair Kilgour - Parkwalk Advisors

ALASTAIR KILGOUR

PARKWALK ADVISORS

Representing Parkwalk Advisors, which he co-founded in 2009, Alastair was a Partner of Lazard LLP, Director of BNP and a Founder Partner of Ark Securities. He has analyzed and advised both private and public companies on strategy, development, fund-raising and exits. He oversees the investment process at Parkwalk and he sits on various portfolio company Boards, including Congenica, PhoreMost, PredictImmune, Aqdot and Mirriad.

Joanna Green - Ahren Innovation Capital

JOANNA GREEN

AHREN INNOVATION CAPITAL

Joanna Green is a Principal at Ahren Innovation Capital.

Joanna joined Ahren from the Boston Consulting Group (BCG), where she worked on strategic projects across a range of industries including healthcare, insurance and the public sector.

Joanna holds a PhD in fetal immunology, focusing on childhood leukemia, and a First-Class Master’s and undergraduate degree from the University of Oxford.

Dr. Hiromichi Kimura - Astellas Venture Management

DR. HIROMICHI KIMURA

Astellas Venture Management

Hiro has extraordinary R&D experiences over 20 years. He leads multiple angle-organization management of both new investments including LP position and portfolio companies in Board, SAB, KOL meetings. His expertise has been delegated to any due diligence with innovative R&D activities. He has served as Head of Alliance & Management in Drug discovery research at Astellas including research collaboration and post-merger integration of Biotech and Venture. Hiro has also conducted drug discovery in Oncology in Astellas. Before that, Hiro led many new programs as head of pharmacology in Oncology Drug Discovery, Takeda Pharmaceutical Company, and Drug Discovery department in Millennium: Takeda Oncology Company. In this capacity of an officer with high responsibility, he was responsible for drug discovery from early to late-stage including innovative technologies at Japan facility as well as global drug discovery initiatives. Hiro served a number of academic lectures with academic appointments. Prior to his tenure at Takeda, he was dedicated to conducting basic research, drug discovery and translational research in St Jude Children’s Research Hospital (Dr Tom Curran, FRS, currently Executive Director and Chief Scientific Officer of the Children’s Research Institute, Children’s Mercy), in collaboration with Genentech (Dr Fred de Savage, Vice president) and Curis (Dr Lee Rubin, CSO, currently Professor at Harvard University).

Hiro received a Ph.D. with distinction in Epigenetics, Cellular Molecular Biology/Veterinary Medical Sciences from the University of Tokyo.
Currently, Hiro is appointed as a lecturer of World-leading Innovative Graduate Study Program for Life Science and Technology at the University of Tokyo.

Paul Tselentis - 24Haymarket

PAUL TSELENTIS

24Haymarket

Paul is a co-founder and CEO of 24Haymarket. He previously spent over ten years working in private equity at The Carlyle Group and CCMP Capital and in Investment Banking at Lehman Brothers. Paul has a BA (magna cum laude) in Economics from Harvard University.

Dr. Jane Osbourn OBE - CHAIR
Dr. Darrin M. Disley OBE - CEO
Dr. Karin Schmitt - CBO
Prof. Julian Gough - CTO (Co-founder)
Dr. Lorenz Mayr
Alastair Kilgour - Parkwalk Advisors
Joanna Green - Ahren Innovation Capital
Dr. Hiromichi Kimura - Astellas Venture Management
Paul Tselentis - 24Haymarket

Our

Board of directors